Selected research
Industry Research
Doxorubicin Hydrochloride Industry Research Report 2026
Market perspective
The global Doxorubicin Hydrochloride market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Doxorubicin Hydrochloride is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Doxorubicin Hydrochloride is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Doxorubicin Hydrochloride is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Doxorubicin Hydrochloride include Medac GmbH, Sun Pharmaceutical, Viatris, Fresenius Kabi, Zhejiang Hisun (HanHui Pharmaceuticals), Pfizer, Shanxi PUDE Pharmaceutical, Shenzhen Main Luck Pharmaceuticals and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Doxorubicin Hydrochloride market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Doxorubicin Hydrochloride Market by Company
Medac GmbH
Sun Pharmaceutical
Viatris
Fresenius Kabi
Zhejiang Hisun (HanHui Pharmaceuticals)
Pfizer
Shanxi PUDE Pharmaceutical
Shenzhen Main Luck Pharmaceuticals
Teva
Doxorubicin Hydrochloride Segment by Type
10mg
20mg
50mg
200mg
Others
Doxorubicin Hydrochloride Segment by Application
Malignant Lymphoma
Lung Cancer
Acute Leukemia
Breast Cancer
Others
Doxorubicin Hydrochloride Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Doxorubicin Hydrochloride market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Doxorubicin Hydrochloride and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Doxorubicin Hydrochloride.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Doxorubicin Hydrochloride manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Doxorubicin Hydrochloride by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Doxorubicin Hydrochloride in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 10mg
- 20mg
- 50mg
- 200mg
- Others
Applications
- Malignant Lymphoma
- Lung Cancer
- Acute Leukemia
- Breast Cancer
- Others
Companies covered
- Medac GmbH
- Sun Pharmaceutical
- Viatris
- Fresenius Kabi
- Zhejiang Hisun (HanHui Pharmaceuticals)
- Pfizer
- Shanxi PUDE Pharmaceutical
- Shenzhen Main Luck Pharmaceuticals
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Doxorubicin Hydrochloride Market Size (2021-2032)
- 2.2.2 Global Doxorubicin Hydrochloride Sales (2021-2032)
- 2.2.3 Global Doxorubicin Hydrochloride Market Average Price (2021-2032)
- 2.3 Doxorubicin Hydrochloride by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 10mg
- 2.3.3 20mg
- 2.3.4 50mg
- 2.3.5 200mg
- 2.3.6 Others
- 2.4 Doxorubicin Hydrochloride by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Malignant Lymphoma
- 2.4.3 Lung Cancer
- 2.4.4 Acute Leukemia
- 2.4.5 Breast Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Doxorubicin Hydrochloride Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Doxorubicin Hydrochloride Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Doxorubicin Hydrochloride Revenue of Manufacturers (2021-2026)
- 3.4 Global Doxorubicin Hydrochloride Average Price by Manufacturers (2021-2026)
- 3.5 Global Doxorubicin Hydrochloride Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Doxorubicin Hydrochloride, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Doxorubicin Hydrochloride, Product Type & Application
- 3.8 Global Manufacturers of Doxorubicin Hydrochloride, Established Date
- 3.9 Global Doxorubicin Hydrochloride Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Medac GmbH
- 4.1.1 Medac GmbH Company Information
- 4.1.2 Medac GmbH Business Overview
- 4.1.3 Medac GmbH Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Medac GmbH Doxorubicin Hydrochloride Product Portfolio
- 4.1.5 Medac GmbH Recent Developments
- 4.2 Sun Pharmaceutical
- 4.2.1 Sun Pharmaceutical Company Information
- 4.2.2 Sun Pharmaceutical Business Overview
- 4.2.3 Sun Pharmaceutical Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Doxorubicin Hydrochloride Product Portfolio
- 4.2.5 Sun Pharmaceutical Recent Developments
- 4.3 Viatris
- 4.3.1 Viatris Company Information
- 4.3.2 Viatris Business Overview
- 4.3.3 Viatris Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Viatris Doxorubicin Hydrochloride Product Portfolio
- 4.3.5 Viatris Recent Developments
- 4.4 Fresenius Kabi
- 4.4.1 Fresenius Kabi Company Information
- 4.4.2 Fresenius Kabi Business Overview
- 4.4.3 Fresenius Kabi Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Fresenius Kabi Doxorubicin Hydrochloride Product Portfolio
- 4.4.5 Fresenius Kabi Recent Developments
- 4.5 Zhejiang Hisun (HanHui Pharmaceuticals)
- 4.5.1 Zhejiang Hisun (HanHui Pharmaceuticals) Company Information
- 4.5.2 Zhejiang Hisun (HanHui Pharmaceuticals) Business Overview
- 4.5.3 Zhejiang Hisun (HanHui Pharmaceuticals) Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zhejiang Hisun (HanHui Pharmaceuticals) Doxorubicin Hydrochloride Product Portfolio
- 4.5.5 Zhejiang Hisun (HanHui Pharmaceuticals) Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Doxorubicin Hydrochloride Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Shanxi PUDE Pharmaceutical
- 4.7.1 Shanxi PUDE Pharmaceutical Company Information
- 4.7.2 Shanxi PUDE Pharmaceutical Business Overview
- 4.7.3 Shanxi PUDE Pharmaceutical Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Shanxi PUDE Pharmaceutical Doxorubicin Hydrochloride Product Portfolio
- 4.7.5 Shanxi PUDE Pharmaceutical Recent Developments
- 4.8 Shenzhen Main Luck Pharmaceuticals
- 4.8.1 Shenzhen Main Luck Pharmaceuticals Company Information
- 4.8.2 Shenzhen Main Luck Pharmaceuticals Business Overview
- 4.8.3 Shenzhen Main Luck Pharmaceuticals Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shenzhen Main Luck Pharmaceuticals Doxorubicin Hydrochloride Product Portfolio
- 4.8.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
- 4.9 Teva
- 4.9.1 Teva Company Information
- 4.9.2 Teva Business Overview
- 4.9.3 Teva Doxorubicin Hydrochloride Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Teva Doxorubicin Hydrochloride Product Portfolio
- 4.9.5 Teva Recent Developments
5 Global Doxorubicin Hydrochloride Market Scenario by Region
- 5.1 Global Doxorubicin Hydrochloride Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Doxorubicin Hydrochloride Sales by Region: 2021-2032
- 5.2.1 Global Doxorubicin Hydrochloride Sales by Region: 2021-2026
- 5.2.2 Global Doxorubicin Hydrochloride Sales by Region: 2027-2032
- 5.3 Global Doxorubicin Hydrochloride Revenue by Region: 2021-2032
- 5.3.1 Global Doxorubicin Hydrochloride Revenue by Region: 2021-2026
- 5.3.2 Global Doxorubicin Hydrochloride Revenue by Region: 2027-2032
- 5.4 North America Doxorubicin Hydrochloride Market Facts & Figures by Country
- 5.4.1 North America Doxorubicin Hydrochloride Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Doxorubicin Hydrochloride Sales by Country (2021-2032)
- 5.4.3 North America Doxorubicin Hydrochloride Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Doxorubicin Hydrochloride Market Facts & Figures by Country
- 5.5.1 Europe Doxorubicin Hydrochloride Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Doxorubicin Hydrochloride Sales by Country (2021-2032)
- 5.5.3 Europe Doxorubicin Hydrochloride Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Doxorubicin Hydrochloride Market Facts & Figures by Country
- 5.6.1 Asia Pacific Doxorubicin Hydrochloride Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Doxorubicin Hydrochloride Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Doxorubicin Hydrochloride Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Doxorubicin Hydrochloride Market Facts & Figures by Country
- 5.7.1 South America Doxorubicin Hydrochloride Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Doxorubicin Hydrochloride Sales by Country (2021-2032)
- 5.7.3 South America Doxorubicin Hydrochloride Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Doxorubicin Hydrochloride Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Doxorubicin Hydrochloride Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Doxorubicin Hydrochloride Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Doxorubicin Hydrochloride Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Doxorubicin Hydrochloride Sales by Type (2021-2032)
- 6.1.1 Global Doxorubicin Hydrochloride Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Doxorubicin Hydrochloride Sales Market Share by Type (2021-2032)
- 6.2 Global Doxorubicin Hydrochloride Revenue by Type (2021-2032)
- 6.2.1 Global Doxorubicin Hydrochloride Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Doxorubicin Hydrochloride Revenue Market Share by Type (2021-2032)
- 6.3 Global Doxorubicin Hydrochloride Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Doxorubicin Hydrochloride Sales by Application (2021-2032)
- 7.1.1 Global Doxorubicin Hydrochloride Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Doxorubicin Hydrochloride Sales Market Share by Application (2021-2032)
- 7.2 Global Doxorubicin Hydrochloride Revenue by Application (2021-2032)
- 7.2.1 Global Doxorubicin Hydrochloride Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Doxorubicin Hydrochloride Revenue Market Share by Application (2021-2032)
- 7.3 Global Doxorubicin Hydrochloride Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Doxorubicin Hydrochloride Value Chain Analysis
- 8.1.1 Doxorubicin Hydrochloride Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Doxorubicin Hydrochloride Production Mode & Process
- 8.2 Doxorubicin Hydrochloride Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Doxorubicin Hydrochloride Distributors
- 8.2.3 Doxorubicin Hydrochloride Customers
9 Global Doxorubicin Hydrochloride Analyzing Market Dynamics
- 9.1 Doxorubicin Hydrochloride Industry Trends
- 9.2 Doxorubicin Hydrochloride Industry Drivers
- 9.3 Doxorubicin Hydrochloride Industry Opportunities and Challenges
- 9.4 Doxorubicin Hydrochloride Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst